SCHEMBL3335896

SCHEMBL3335896

O=C(NNc1nc(-c2ccccc2)cs1)c1cccs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 1.00
KDM4E B2RXH2 11/20 1.00
GAA P10253 7/20 1.00
MAPK1 P28482 5/20 1.00
KMT2A Q03164 7/20 0.76
MEN1 O00255 6/20 0.76
HTT P42858 5/20 0.76
NPC1 O15118 3/20 0.76
RAB9A P51151 3/20 0.76
TP53 P04637 1/20 0.76
ALOX15 P16050 1/20 0.76
TSHR P16473 1/20 0.76
HSD17B10 Q99714 1/20 0.76
LMNA P02545 6/20 0.71
ALDH1A1 P00352 5/20 0.71
POLB P06746 1/20 0.70
SMN1; SMN2 Q16637 5/20 0.64
TDP1 Q9NUW8 4/20 0.64
PARP1 P09874 1/20 0.54
SCD O00767 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17107114 0.86 KMT2A (1.00) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3337508 0.83 MAPT (1.00) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3338134 0.82 KDM4E (0.85) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3341776 0.81 MAPT (0.89) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3344724 0.78 KDM4E (1.00) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3338748 0.78 MAPT (0.82) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3343901 0.78 MEN1 (0.77) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3336646 0.77 KDM4E (0.76) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3337873 0.76 MAPT (0.79) MAPTKDM4EGAAMAPK1KMT2A
SCHEMBL3338830 0.76 MEN1 (0.73) MAPTKDM4EGAAMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885KDM4E 4489/4885GAA 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.